Matritech , a Massachusetts-based start-up company , has developed a diagnostic technique that detects bladder cancer more easily-and possibly more effectively-than existing methods can .Others are present in elevated amounts .`` There 's been all this hoopla about genetic screening , but nuclear matrix protein testing could have the biggest impact of all , '' says Lance Willsey of Harvard Medical School .Matritech is initially seeking approval for NMP22 solely to check for recurrences of bladder cancer .Nuclear matrix proteins could represent targets for therapeutic agents , too .